Question 1

What are the potential benefits of participating in this trial compared to standard treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma clinical trial (NCT01220271). Contact the study team or your healthcare provider for specific answers.

Question 2

How will the side effects of LY2157299 compare to those of temozolomide?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma clinical trial (NCT01220271). Contact the study team or your healthcare provider for specific answers.

Question 3

What will the treatment schedule look like, and how often will I need to come in for visits?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma clinical trial (NCT01220271). Contact the study team or your healthcare provider for specific answers.

Question 4

Are there any risks associated with combining these treatments?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma clinical trial (NCT01220271). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma clinical trial (NCT01220271). Contact the study team or your healthcare provider for specific answers.

Question 6

How will my progress be monitored during the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma clinical trial (NCT01220271). Contact the study team or your healthcare provider for specific answers.

What this study is about